Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
4.820
+0.130 (2.77%)
At close: Dec 20, 2024, 4:00 PM
4.810
-0.010 (-0.21%)
After-hours: Dec 20, 2024, 5:25 PM EST
Ardelyx Revenue
Ardelyx had revenue of $98.24M in the quarter ending September 30, 2024, with 74.21% growth. This brings the company's revenue in the last twelve months to $251.85M, up 87.57% year-over-year. In the year 2023, Ardelyx had annual revenue of $124.46M with 138.61% growth.
Revenue (ttm)
$251.85M
Revenue Growth
+87.57%
P/S Ratio
4.48
Revenue / Employee
$943,255
Employees
267
Market Cap
1.14B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Embecta | 1.12B |
Artivion | 384.90M |
Innoviva | 352.75M |
CareDx | 312.78M |
Weave Communications | 195.84M |
Establishment Labs Holdings | 153.07M |
Syndax Pharmaceuticals | 16.00M |
ARS Pharmaceuticals | 2.57M |
ARDX News
- 27 days ago - Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It - Seeking Alpha
- 4 weeks ago - Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability - Seeking Alpha
- 6 weeks ago - Ardelyx Responds to District Court Decision Granting Motion to Dismiss - GlobeNewsWire
- 6 weeks ago - Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting - GlobeNewsWire